Risperdal News Log

Paxil News from WorstDrugs.com

Thu, 1 Dec 2005 07:47:32 -0400

Paxil and Birth Defects December 2005 You should consult with your doctor immediately if you are taking paroxetine and are pregnant and particularly if you are in your first trimester. Suddenly stopping paroxetine and drugs like it may result in a withdrawal syndrome. See the warning statement above.

Suicide Risk in Youth: Possible Strattera Connection

Thu, 1 Dec 2005 07:46:48 -0400

Worst Drugs: December 2005
The Food and Drug Administration (FDA) issued a Public Health Advisory on Sept. 29, 2005 to warn of suicidal thinking in children and adolescents being treated with atomoxetine (STRATTERA) for attention deficit hyperactivity disorder (ADHD). There is no convincing evidence that atomoxetine (STRATTERA) is as effective or as well tolerated as stimulants such as methylphenidate (CONCERTA, and others) for treatment of ADHD.

PSYCHOSIS DRUG RISKS ARE NOTED

Fri, 28 Oct 2005 06:32:24 -0400

Frail, elderly patients with Alzheimer's disease who are given widely used antipsychotic drugs such as Zyprexa and Risperdal have a higher risk of dying than patients who are given sugar pills, and doctors should be cautious in prescribing the drugs, according to a new analysis of earlier studies. The report is likely to complicate the limited choices that families face while caring for elderly patients with Alzheimer's. And it lends support to a decision by the Food and Drug Administration earlier this year to require warning labels on the drugs. The drugs are approved for the treatment of psychoses in adults but have not been specifically approved for use among elderly patients with dementia, so physicians prescribing them for this group are relying on their clinical judgment. Experts said the new study should help doctors better weigh the risks and benefits. Shankar Vedantam, The Washington Post, 10/19/2005

FDA MAY REQUIRE LONGER STUDIES BEFORE CLEARING PSYCHIATRIC DRUGS

Fri, 21 Oct 2005 07:13:12 -0400

Federal regulators are considering requiring drugmakers to perform longer-term studies of many psychiatric medications before they can be approved for marketing in the U.S. In documents posted on its website, the Food and Drug Administration said for the past six months, it has been asking manufacturers to provide "longer- term efficacy data" for psychiatric drugs that treat chronic conditions. But the shift has met with resistance from companies and some researchers, who have said it will slow the process of developing new drugs, said Thomas Laughren, acting director of the agency's division of psychiatry products.

Leila Abboud And Anna Wilde Mathews, The Wall Street Journal, 10/18/2005.

Study Finds Little Advantage In New Schizophrenia Drugs

Fri, 7 Oct 2005 10:18:16 -0400

A landmark government-financed study that compared drugs used to treat schizophrenia has confirmed what many psychiatrists long suspected: newer drugs that are highly promoted and widely prescribed offer few -- if any -- benefits over older medicines that sell for a fraction of the cost. http://www.ncpa.org/prs/cd/2005/20050920.htm

Marketing of Leading Prescription Treatments for Schizophrenia, Including RISPERDAL(R) and RISPERDAL(R) CONSTA(R)

Mon, 19 Sep 2005 17:10:28 -0400

Results from the National Institutes of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial, published in the September 22 issue of the New England Journal of Medicine, underscore that people with schizophrenia need many medication options because what works well for one patient may not work as well for another. The efficacy results for RISPERDAL® (risperidone) did not demonstrate the full efficacy of RISPERDAL® because many patients in the CATIE trial received doses that were too low(i). Further, the study highlights the need for newer therapies that can improve adherence to medication and address other unmet needs of these patients who battle this lifelong disease. http://biz.yahoo.com/prnews/050919/nym206.html?.v=17

What are the possible side effects of risperidone?

Sun, 17 Jul 2005 10:07:11 -0400

Contact your doctor immediately if you experience fever, sweating, severe muscle stiffness (rigidity), confusion, fast or irregular heart beat. These could be symptoms of a potentially fatal side effect called Neuroleptic Malignant Syndrome (NMS).

Physchiatric Drugs in Pediatric patients. Resources

Sun, 17 Jul 2005 09:02:50 -0400

1. Burns BJ, Costello EJ, Angola A, et al. Children's mental health service use across service sectors. Health Aff (Millwood). 1995;14:147-159

2. Shaffer D, Gould MS, Fisher P, et al. Psychiatric diagnosis in child and adolescent suicide. Arch Gen Psychiatry. 1996;53:339-348

3. Costello EJ, Angold A, Keeler GP. Adolescent outcomes of childhood disorders: the consequences of severity and impairment. J Am Acad Child Adolesc Psychiatry. 1999;38:121-128

4. Costello EJ, Messer SC, Bird HR, et al. The prevalence of serious emotional disturbance: a re-analysis of community studies. J Child Film Stud. 1998;7:411-432

5. Roberts RE, Attkisson CC, Rosenblatt A. Prevalence of psychopathology among children and adolescents. Am J Psychiatry. 1998;155:715-725

6. US Public Health Service. Report of the Surgeon General's Conference on Children's Mental Health: A National Action Agenda. Washington, DC: Department of Health and Human Services; 2000

7. Methods of suicide among persons aged 10-19 years-United States, 1992-2001. MMWR Surveill Summ. 2004;53:471-474

8. Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep. 2003;52:1-88

9. Burns BJ, Hoagwood KE. Preface: evidence-based practice, part 1: research update. Child Adolesc Psychiatr Clin N Am. 2004;13:xi- xiii

10. Leonard HL, March J, Rickler KC, et al. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997;36:725-736

11. Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003;157:17-25

12. Zito JM, Safer DJ, DosReis S, et al. Rising prevalence of antidepressants among US youths. Pediatrics. 2002;109:721-727

13. Chan RT, Rey JM, Hazell PL. Clinical practice guidelines for depression in young people: are the treatment recommendations outdated? Med J Aust. 2002;177:448-451

14. Rushton JL, Clark SJ, Freed GL. Pediatrician and family physician prescription of selective serotonin reuptake inhibitors. Pediatrics. 2000; 105(6). Available at: www.pediatrics.org/cgi/ content/full/105/6/e82

15. Safer DJ, Zito JM, DosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry. 2003;160:438-449

16. Olfson M, Marcus SC, Weissman MM, et al. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry. 2002;41:514-521

17. Rigoni GC, US Food and Drug Administration, Division of Surveillance, Research and Communication Support. Drug Utilization for Selected Antidepressants Among Children & Adolescents in the U.S. February 2, 2004. Available at: www.fda.gov/ohrms/dockets/ac/ 04/slides/ 4006S1_04_RigonLfiles/frame.htm. Accessed December 7, 2004

18. Yaffe SJ, Aranda JV. Introduction and historical perspectives. In: Yaffe SJ, Aranda JV, eds. Pediatric Pharmacology: Therapeutic Principles in Practice. 2nd ed. Philadelphia, PA: WB Saunders Company; 1992:3-9

19. Hazell P, O'Connell D, Heathcote D, et al. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta- analysis. BMJ. 1995; 310:897-901

20. Gilman JT. Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications. Clin Pharmacokinet. 1990;19:1-10

21. Brown RD, Campoli-Richards DM. Antimicrobial therapy in neonates, infants and children. Clin Pharmacokinet. 1989;17(suppl 1):105-115

22. Rane A, Wilson JT. Clinical pharmacokinetics in infants and children. Clin Pharmacokinet. 1976;1:2-24

23. Kauffman RE, Kearns GL. Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clin Pharmacokinet. 1992;23: 10-29

24. Butler DR, Kuhn RJ, Chandler MH. Pharmacokinetics of anti- infective agents in paediatric patients. Clin Pharmacokinet. 1994;26:374-395

25. Kutcher S, Boulos C, Ward B, et al. Response to desipramine treatment in adolescent depression: a fixed-dose, placebo- controlled trial. J Am Acad Child Adolesc Psychiatry. 1994;33:686- 694

26. Geller B, Reising D, Leonard H, et al. Critical Review Of Tricyclic Antidepressant Use In Children And Adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38: 5:513-516

27. US Department of Health and Human Services and Food and Drug Administration. Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients, 1998. 21 CFR Parts 201, 312, 314, 601

28. US Department of Health and Human Services and Food and Drug Administration. The Pediatric Exclusivity Provision: January 2001 Status Report to Congress. Rockville, MD: Food and Drug Administration; 2001

29. US Department of Health and Human Services and Food and Drug Administration. Guidance for Industry: Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act. Rockville, MD: Center for Drug Evaluation and Research; 1999

30. US Food and Drug Administration, Center for Drug Evaluation and Research. Docket No. 98N-0056 Update of List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population: Drugs and Biologies (May 20, 2001). Available at: www.fda.gov/cder/pediatric/peddrugsfinal.htm. Accessed November 10, 2004

31. Best Pharmaceuticals for Children Act of 2002, Pub L No. 107- 109

32. Pediatric Research Equity Act of 2003, Pub L No. 108-155 33. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergenc\e of suicidal tendencies. Drug Saf. 1993;8:186-212

34. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry. 1991; 52:491-493

35. Mann JJ, Kapur S. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry. 1991;48: 1027-1033 36. Wirshing WC, Van Putten T, Rosenberg J, et al. Fluoxetine, akathisia, and suicidality: is there a causal connection? Arch Gen Psychiatry. 1992; 49:580-581

37. Donovan S, clayton A, Beeharry M, et al. Deliberate self- harm and antidepressant drugs. Investigation of a possible link. Er J Psychiatry. 2000;177:551-556

38. Department of Health and Human Services, Public Health Service, Food and Drug Administration. Psychopharmacological Drugs Advisory Committee. September 20, 1991. Available at: www.fda.gov/ ohrms/ dockets/ac/prozac/2443T1.PDF. Accessed November 10, 2004

39. Antonuccio DO, Danton WG, DeNelsky GY, et al. Raising questions about antidepressants. Psychother Psychosom. 1999;68:3-14 40. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330:396

41. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005;330:385

42. Lane R, Baldwin D. Selective serotonin reuptake inhibitor- induced serotonin syndrome: review. J Clin Psychopharmacol. 1997;17:208-221

43. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom. 2003;72:71-79 44. Preda A, MacLean RW, Mazure CM, et al. Antidepressant- associated mania and psychosis resulting in psychiatric admissions. J Clin Psychiatry. 2001;62:30-33

45. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a metaanalysis of antidepressant medication. Prev Treat. 1998;1. Available at: www.journals.apa.org/prevention/volume1/ pre0010002a.html. Accessed May 19, 2005

46. Kirsch I, Moore TJ, Scoboria A, et al. The Emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat. 2002;5. Available at: www.journals.apa.org/prevention/volume5/pre0050023a.html. Accessed May 19, 2005

47. Wilens TE, Biederman J, Kwon A, et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol. 2003;13:143-52

48. King RA, Riddle MA, Chappell PB, et al. Emergence of self- destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry. 1991;30(2):179-186

49. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40:762- 772 50. US Department of Health and Human Services, Public Health Service, Food and Drug Administration, et al. Memorandum: Overview for February 2, 2004 Meeting of Psychopharmacological Drugs Advisory Committee (PDAC) and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee (Peds AC). January 2, 2004. Available at: www.fda.gov/ohrms/dockets/ac/04/briefing/4006B1_01_Overview%20 Memo.htm. Accessed November 10, 2004

51. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive- behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292:807-820

52. US Food and Drug Administration, Center for Drug Evaluation and Research. Frequently Asked Questions on Pdiatrie Exclusivity (505A), the Pediatric "Rule," and Their Interaction. Available at: www.fda.gov/ cder/pediatric/faqs.htm. Accessed November 10, 2004

53. Greenhill LL, Vitiello B, Fisher P, et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2004; 43:1488-1496

54. Hammad TA. Results of the Analysis of Suicidality in Pediatric Trials of Newer Antidepressants. Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee. September 13, 2004-September 14, 2004. Available at: www.fda.gov/ohrms/ dockets/ ac/04/slides/2004-4065S1_08_FDA-Hammad_files/frame.htm. Accessed November 10, 2004

55. Newman TB. A black-box warning for antidepressants in children? N Engl J Med. 2004;351:1595-1598

56. Rothman KJ, Greenland S. Modern Epidemiology. Philadelphia, PA: Lippincott-Raven; 1998

57. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363:1341- 1345

58. Jureidini JN, Doecke CJ, Mansfield PR, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ. 2004;328:879-883

59. American Academy of Child & Adolescent Psychiatry. AACAP Work Force Data Sheet. Available at: www.aacap.org/training/ workforce.hcm. Accessed November 30, 2004

60. Editorial. FDA blues. Washington Post. November 26, 2004:A38

61. Fontanarosa P, Rennie D, DeAngelis C. Postmarketing surveillance-lack of vigilance, lack of trust. JAMA. 2004;292:2647- 2650

62. Psaty B, Furberg C, Ray W, et al. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA. 2004;292:2622- 2631

63. US Department of Health and Human Services, Food and Drug Administration. FDA Fact Sheet: FDA Improvements in Drug Safety Monitoring. February 15, 2005. Available at: www.fda.gov/oc/ factsheets/ drugsafety.html. Accessed February 25, 2005

64. Walkup JT, Labellarte MJ, Riddle MA, et al. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001;344:1279-1285

65. Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research. Antidepressant Use in Children, Adolescents, and Adults: Labeling Template. Available at: www.fda.gov/cder/drug/antidepressants/ PLtemplate.pdf. Accessed February 28, 2005

66. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acnd Child Adolesc Psychiatry. 1998; 37(suppl):63S-83S

67. Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ. 2005;330:389

68. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs. 2004;18: 1119-1132

More and more experts say ADHD can be a gift rather than a malady

Sat, 16 Jul 2005 09:11:35 -0400

Among the celebrated thinkers believed to have had ADHD or ADD (attention deficit disorder, where the energy level is lower), are Winston Churchill, Albert Einstein and Galileo. Musicians like Beethoven also are thought to have had the disorder. People with ADHD can think outside of the box and are willing to take risks, which can make them successful entrepreneurs.

Celebs take on issue of psychiatric drugs

Thu, 14 Jul 2005 08:59:21 -0400

http://hartfordadvocate.com/gbase/News/content?oid=oid:118922

Perhaps Tom Cruise's points hould have been:
1) People do change when they use psych drugs -- they are on drugs! Not medicines! Get the difference? Medicines cure actual illnesses. Drugs mask personal problems or actual physical issues no differently than street drugs or liquor do. LSD was once a psychiatric drug. So the actual problems are never solved unless the individual works it out himself or with friends, or finds real help. But we also have the problem of the side effects of these drugs which brings me to my next point. This is the danger Cruise warned of.

2) In June, the FDA warned that the use of the drugs Concerta, Ritalin, Straterra and Adderall can produce "visual hallucinations, suicidal ideation, psychotic behavior, as well as aggression or violent behavior" in children.

3) The entire premise for the use of these drugs is based on the claim of a "medical" cause for peoples' emotional issues -- the so-called "chemical imbalance." American Psychiatric Association President Steven Sharfstein admitted recently that there is no way to test for a "chemical imbalance" so none is ever done. Again, Cruise is right and they concede.